Last Updated on December 31, 2023 by The Health Master
Download NPPA notification No. S.O. 2123(E) dt 04-05-2023, the link is given below: The National Pharmaceutical Pricing Authority (NPPA) has fixed the retail prices of 15 formulations under the Drugs (Prices Control) Order, 2013, vide S.O. 2123(E) dt 04-05-2023 based on the decision of the 112th Authority meeting dated 01-05-2023.
This price fixation followed the decision of the 112th Authority meeting on May 01, 2023
The notification states as under:
In exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S. O. 5249(E) dated 11th November, 2022 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA), hereby fixes, the price as specified in column (6) of the table herein below as the retail price, exclusive of Goods and Services Tax, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company, as specified in the corresponding entries in columns (3), (4) and (5) thereof;
Table is given below the article
Note:
(a) The manufacturer of the above-mentioned formulations, i.e., the “new drug” under paragraph 2(1)(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove.
(b) The manufacturer may add Goods and Services Tax only if they have paid actually or it is payable to the Government on the retail price mentioned in column (6) of the above said table.
(c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013.
The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.
(d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.
(e) The above mentioned retail price is applicable only to the individual manufacturer / marketer as mentioned above i.e.. who have applied for the same by submitting Form-I for price fixation / revision as stipulated under DPCO, 2013 and subject to fulfilment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules,
including manufacturing license permission from the competent authority, i.e., the central or state licensing authority, as may be applicable, by the concerned manufacturer/marketing company.
(f) In case the retail price of any of the aforesaid formulations is not complied with, as per the instant price notification and notes specified hereinabove, then the concerned manufacturer / marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.
(g) Consequent to the fixation of retail price of such formulation as specified in column (2) of the above table with the strength and name of Manufacturer & Marketing Companies specified in the corresponding entries in Column (3) & (5) thereof, the price order(s) fixing the retail price of the formulation with specified strength for that Manufacturer & Marketing
Companies as specified in corresponding entries in Columns (2), (3), and (5) thereof, if any, issued prior to this notification, stand superseded.
Latest on National Pharmaceutical Pricing Authority (NPPA)
Latest notifications – DPCO / NPPA
NPPA updated price lists: Download
Latest Notifications: EC Act (Essential Commodities Act)
NPPA fixed retail price of 25 formulations: March 2023
NPPA fixed revised retail price of 1 formulation: February 2023
NPPA fixed Ceiling price of 1 scheduled formulation: February 2023
NPPA revised Ceiling price of 80 scheduled formulations: February 2023
USFDA gives final approval for Ephedrine Sulfate Injection
Revising DT limit for Soft Gelatin Capsules: Pharma Industry seek solutions
Drug alert: 36 out of 895 samples declared as NSQ in April 2023
Revising DT limit for Soft Gelatin Capsules: Pharma Industry seek solutions
USFDA issues Form 483 with zero observations to Pharma MSMEs: Gujarat
Govt to amend New Drugs and Clinical Trials Rules 2019 (NDCTR)
USFDA completes inspection of Hikal Pharma with zero observation
Govt amends Para 5 and Para 18 of DPCO 2013
USFDA issues marketing denial for 6,500 flavored E-cigarettes
Surprise Inspection of 35 Medical Store: 8 Suspended, One Sealed
Table
| Sl. No . | Name of the Formulation / Brand Name | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
| (1) | (2) | (3) | (4) | (5) | (6) |
| 1 | Amoxycillin and Potassium Clavulanate Oral Suspension (Combi pack with Sterile Water for Reconstitution of Dry Syrup) | Each combi pack contains: Amoxycillin and Potassium Clavulanate Oral suspension IP Composition: Each 5ml of reconstituted suspension contains: Amoxycillin Trihydrate IP eq. to Amoxycillin 600mg Potassium Clavulanate Diluted IP eq. to Clavulanic Acid 42.9mg 2 Ampoules of sterile water for reconstitution of dry syrup each ampoule contains: sterile water for injection IP 25ml | Each Combi Pack | M/s Malik Lifesciences Pvt. Ltd. / M/s Dr. Reddy’s Laboratories Limited | 162.1 1 |
| 2 | Paracetamol, Phenylephrine Hydrochloride & Chlorpheniram ine maleate Tablets | Each uncoated tablet contains: Paracetamol IP 500mg Phenylephrine Hydrochloride IP 10mg Chlorpheniramine maleate IP 2mg | 1 Tablet | M/s East African (India) Overseas / M/s Alkem Laboratories Ltd. | 4.42 |
| 3 | Amoxycillin & Potassium Clavulanate Tablets IP | Each film coated tablet contains: Amoxycillin Trihydrate IP eq. to Amoxycillin 875mg Potassium Clavulanate Diluted IP eq. to Clavulanic Acid 125mg | 1 Tablet | M/s Theon Pharmaceuticals Limited / M/s FDC Limited | 33.92 |
| 4 | Ofloxacin and Betamethason e Sodium Phosphat Eye / Ear Drops | Composition: Ofloxacin IP 0.3% w/v Betamethasone Sodium Phosphate IP 0.1% w/v Benzalkonium Chloride Solution IP 0.02% v/v (As preservative) | 1 ml | M/s Skymap Pharmaceuticals Pvt. Ltd./ M/s German Remedies Pharmaceuticals Pvt. Ltd. | 1.45 |
| 5 | Tranexamic Acid and Etamsylate Tablets | Each film coated tablet contains: Etamsylate BP 250mg Tranexamic Acid IP 500mg. | 1 Tablet | M/s Windlas Biotech Pvt. Ltd. / M/s Torrent Pharmaceuticals Ltd. | 23.37 |
| 6 | Aceclofenac and Paracetamol Tablets | Each film coated tablet contains: Aceclofenac IP 100mg Paracetamol IP 325mg | 1 Tablet | M/s Aagya Biotech Pvt. Ltd. / M/s German Remedies Pharmaceuticals Pvt. Ltd. | 4.83 |
| 7 | Calcium, Vitamin D3, Mecobalamin, L-Methylfolate Calcium & Pyridoxal-5- Phosphate Tablets | Each film coated tablet contains: Calcium Carbonate IP 1250mg eq. to Elemntal Calcium 500mg Vitamin D3 IP 2000 IU Mecobalamin IP 1500mcg L-Methylfolate Calcium 1mg Pyridoxal-5-Phosphate 20mg | 1 Tablet | M/s Akums Drugs & Pharmaceuticals Ltd. / M/s Emcure Pharmaceuticals Ltd. | 18.36 |
| 8 | Itraconazole Capsules 65mg (Supra- Bioavailable Formulation) | Each hard gelatin capsule contains: Itraconazole BP 65mg | 1 Capsule | M/s Ravenbhel Healthcare Pvt. Ltd. / M/s Aristo Pharmaceuticals Pvt. Ltd. | 11.94 |
| 9 | Chlorhexidine gluconate, Metronidazole and Lignocaine Hydrochloride Gel | Composition: Chlorhexidine gluconate solution IP eq. to Chlorhexadine 1 % w/w, Metronidazole Bezoate IP eq. to Metronidazole 1% w/w Lignocaine Hydrochloride IP 2% w/w | 1 GM | M/s Alaina Healthcare Pvt. Ltd. / M/s Abbott Healthcare Pvt. Ltd. | 3.75 |
| 10 | Itraconazole Capsules 65mg (Supra- Bioavailable Formulation) | Each hard gelatin capsule contains:Itraconazole BP 65mg | 1 Capsule | M/s Ravenbhel Healthcare Pvt. Ltd. / M/s Emcure Pharmaceuticals Limited | 11.94 |
| 11 | Itraconazole Capsules 130mg (Supra- Bioavailable Formulation) | Each hard gelatin capsule contains: Itraconazole BP 130mg | 1 Capsule | M/s Ravenbhel Healthcare Pvt. Ltd. / M/s Emcure Pharmaceuticals Limited | 20.72 |
| 12 | Pantoprazole (EC) and Levosulpiride (SR) Capsules | Each hard gelatin capsule contains: Pantoprazole Sodium IP eq. to Pantoprazole 40mg (as enteric coated pellets) Levosulpiride 75mg (As sustained release pellets) | 1 Capsule | M/s Theon Pharmaceuticals Ltd. / M/s Cadila Pharmaceuticals Ltd. | 16.15 |
| 13 | Linezolid Infusion | Each 100ml contains: Linezolid IP 200mg Dextrose (Anhydrous) 5% w/v Water for Injection IP | 1 ml | M/s AXA Parenterals Ltd. / M/s Themis Medicare Limited | 1.36 |
| 14 | Bisoprolol Fumarate and Amlodipine Tablets | Each film coated tablet contains: Bisoprolol Fumarate IP 5mg Amlodipine Besylate IP Eq. to Amlodipine 5mg | 1 Tablet | M/s Swiss Garniers Biotech Pvt. Ltd. / M/s Zydus Healthcare Limited | 8.34 |
| 15 | Alpha Lipoic Acid + Mecobalamin + Myo-Inositol + Folic Acid + Pyridoxine Hydrochloride + Chromium Picolinate and Benfortiamine Tablets | Each film coated table contains: Alpha Lipoic Acid IP 200mg Mecobalamin IP 1500mcg Myo-Inositol IP 100mg Folic Acid IP 1.5mg Pyridoxine Hydrochloride IP 3mg Chromium Picolinate IP eq. to Elemental chromium 200mcg Benfortiamine 200mg | 1 Tablet | M/s Pure and Cure Healthcare Pvt. Ltd. / M/s Zydus Healthcare Limited | 22.86 |
CORRIGENDUM
S.O. 2167(E) dt 11-05-2023
Instead of
| Sl. No . | Name of the Formulation / Brand Name | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
| (1) | (2) | (3) | (4) | (5) | (6) |
| 4 | Ofloxacin and Betamethason e Sodium Phosphat Eye / Ear Drops | Composition: Ofloxacin IP 0.3% w/v Betamethasone Sodium Phosphate IP 0.1% w/v Benzalkonium Chloride Solution IP 0.02% v/v (As preservative) | 1 ml | M/s Skymap Pharmaceuticals Pvt. Ltd./ M/s German Remedies Pharmaceuticals Pvt. Ltd. | 1.45 |
Read as
| Sl. No . | Name of the Formulation / Brand Name | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
| (1) | (2) | (3) | (4) | (5) | (6) |
| 4 | Ofloxacin and Betamethason e Sodium Phosphat Eye / Ear Drops | Composition: Ofloxacin IP 0.3% w/v Betamethasone Sodium Phosphate IP 0.1% w/v Benzalkonium Chloride Solution IP 0.02% v/v (As preservative) | 1 ml | M/s Skymap Healthcare Pvt. Ltd./ M/s German Remedies Pharmaceuticals Pvt. Ltd. | 1.45 |
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
